Back your fave M&As in Merger Madness

For the irrepressible matchmakers among you, we offer the Wall Street Journal Health Blog's annual March Madness bracket, pharma-style. This time, the subject is--yes--M&A. The blogsters have paired the engaged couples--Pfizer/Wyeth, Roche/Genentech, Eli Lilly/ImClone, Merck/Schering-Plough--and put together the wallflowers, too. So Johnson & Johnson is bracketed with Amgen, Sanofi-Aventis with Bristol-Myers Squibb, et al. Check it out. Report

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.